li001

5-Year CheckMate 274 Results Show Long-Term Benefit of Adjuvant Nivolumab in High-Risk Bladder Cancer

Treatment /

The 5-year results of the CheckMate 274 trial show that adjuvant nivolumab (Opdivo) provides lasting benefits for patients with high-risk muscle-invasive urothelial carcinoma (MIUC) after radical surgery. With nearly five years of follow-up, nivolumab significantly improved outcomes compared with placebo. The median disease-free survival was 21.9 months with nivolumab, compared with 11.0 months with placebo—almost double. […]

5-Year CheckMate 274 Results Show Long-Term Benefit of Adjuvant Nivolumab in High-Risk Bladder Cancer Read More »

Early Chromosome 1q Changes Linked to Pancreatic Cancer Risk

Research Advances /

Researchers discovered that extra copies of chromosome 1q drive early-stage pancreatic cancer. Unlike small mutations, these large chromosomal changes appear in nearly 40% of tumors and often show up in precancerous lesions before other mutations occur. The researchers identified two key genes, NCSTN and PSEN2, on chromosome 1q that regulate cell behavior. Using whole-genome sequencing and

Early Chromosome 1q Changes Linked to Pancreatic Cancer Risk Read More »

AI Model Improves Tumor Detection and Recurrence Prediction in Cervical Cancer

Technology Innovation /

A new study demonstrates an artificial intelligence (AI) system designed to improve the treatment of cervical cancer by automatically outlining tumors on MRI scans and predicting the risk of local recurrence within five years. Accurate tumor outlining is essential for planning radiotherapy. Researchers developed a 3D deep-learning model called MedNext-7L to perform this task. The model

AI Model Improves Tumor Detection and Recurrence Prediction in Cervical Cancer Read More »

FDA Grants Breakthrough Designation to Subcutaneous Amivantamab for HPV-Unrelated Head and Neck Cancer

Drug Approvals /

The U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to amivantamab plus hyaluronidase-lpuj (Rybrevant Faspro), a subcutaneous treatment for adults with recurrent or metastatic, HPV-unrelated head and neck squamous cell carcinoma (HNSCC) whose disease has worsened after platinum-based chemotherapy and immunotherapy. This designation is based on results from the Phase 1b/2 OrigAMI-4 study.

FDA Grants Breakthrough Designation to Subcutaneous Amivantamab for HPV-Unrelated Head and Neck Cancer Read More »

Luspatercept Improves Transfusion Independence in Lower-Risk MDS

Drug Approvals /

A new study shows that luspatercept-aamt (Reblozyl) is effective and safe for treating anemia in transfusion-dependent, lower-risk Myelodysplastic Syndromes (MDS). About 50% of patients achieved at least eight weeks without needing red blood cell transfusions. Certain groups benefited more. Patients who were ring sideroblast (RS)–positive had higher response rates than RS-negative patients, and those with

Luspatercept Improves Transfusion Independence in Lower-Risk MDS Read More »

FDA Approves First Fixed-Duration, All-Oral Acalabrutinib–Venetoclax Regimen for CLL and SLL

Drug Approvals /

The U.S. Food and Drug Administration has approved a new all-oral treatment combination of acalabrutinib (Calquence) and venetoclax (Venclexta) for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This is the first fixed-duration treatment in the U.S. that combines a BTK inhibitor with venetoclax, meaning patients can complete therapy in a set

FDA Approves First Fixed-Duration, All-Oral Acalabrutinib–Venetoclax Regimen for CLL and SLL Read More »

Bispecific CAR T Therapy LV20.19 Shows Strong Responses but High Immune Toxicity in Relapsed CLL

Treatment /

New data from a phase 1/2 study presented at the Transplantation & Cellular Therapy Meetings show that the bispecific CAR T-cell therapy LV20.19 is highly effective for patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL), but it also brings important safety concerns. In the study of 18 patients who had received a median of

Bispecific CAR T Therapy LV20.19 Shows Strong Responses but High Immune Toxicity in Relapsed CLL Read More »

Clinic Study Identifies P2RX7 as Key Driver of Immunotherapy Resistance in Lung Cancer

Research Advances /

Researchers at have discovered how lung tumors can manipulate the immune system to protect themselves. The study, published in Cancer Immunology Research, helps explain why many patients with non-small cell lung cancer (NSCLC) do not respond well to immunotherapy and points to a possible new treatment target. The research focuses on regulatory T cells, or

Clinic Study Identifies P2RX7 as Key Driver of Immunotherapy Resistance in Lung Cancer Read More »

Pancreatic Cancer Frontline Treatment Expands to Three Options in 2026

Treatment /

In 2026, first-line treatment for metastatic pancreatic cancer has expanded from two main options to three. Doctors must choose carefully because there is still no perfect biomarker to guide decisions. The approval of NALIRIFOX in February 2024, based on the NAPOLI 3 trial, added a new standard to existing treatments. The three main frontline regimens

Pancreatic Cancer Frontline Treatment Expands to Three Options in 2026 Read More »

Clinical Trial Shows 100% Response for Fixed-Duration CLL Therapy

Treatment /

A Phase 2 trial shows that a fixed-duration combination of obinutuzumab and venetoclax is highly effective for untreated Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Leukemia (SLL). All patients responded to treatment, with 90% achieving complete or near-complete remission and 100% reaching undetectable levels of residual disease by the ninth cycle. Three months after treatment,

Clinical Trial Shows 100% Response for Fixed-Duration CLL Therapy Read More »